When an embattled venture capital investor’s plans have been derailed by budgetary constraints, the stage is set for another backer to step in with the capital to galvanise their portfolio businesses.
A recent example of this is the predicament facing commercialisation firm NetScientific, which has allowed investment firm EMV Capital to pick up two University of California healthcare spinouts, cancer diagnostics provider Vortex Biosciences and chronic disease management company Wanda, for a fraction of their most-recently published market valuations.
Having come across the spinouts through its contacts, EMV Capital sensed the opportunity was ripe to invest in medtech and connected health, and committed the resources necessary to aid Wanda and…
